Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HG-102 vs Botox for Glabellar Lines
NCT04944953Phase 1Completed
- Sponsor
- Hugel
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of letibotulinumtoxinA in glabellar lines (2 arms), sponsored by Hugel. Primary endpoints: Adverse event and adverse drug reaction incidence rates and Clinically-relevant changes in vital signs, physical exam, and laboratory testing at 16 weeks. Started Jun 2021; status: completed.
02
Drugs
letibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04944953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944953.